In IMPT-based proton therapy, spot size and lateral penumbra are critical to precisely deliver treatment and spare critical structures close to the target. Using Mevion’s HYPERSCAN PBS with Adaptive Aperture proton MLC, an optimal spot size and sharper penumbra can be achieved at each energy layer of the target, thus creating a more conformal treatment field than previously achievable by relying on small spot sizes alone.
In July, users who have successfully deployed Mevion’s Adaptive Aperture proton MLC in their clinical programs presented at Mevion Industry Symposium at NAPT 2020. The speakers shared the advantages they have experienced and how MLC-enhanced IMPT may further advance the treatment paradigm of proton therapy over IMRT through improved proton dose conformality.
Mevion's Senior VP of Clinical Relationships, Skip Rosenthal (PhD,) introduces the sharing sessions below. These users include Dr. Brian Baumann of Washington University, Hosang Jin (PhD) of the University of Oklahoma, and Dr. Brian Collins of MedStar Georgetown University Hospital.
Watch the symposium recordings here:
Introduction: MLC Based IMPT In Complex Cases
Skip Rosenthal, PhD
Senior VP, Clinical Relationships
Mevion Medical Systems
Comparative Effectiveness of Proton vs. Photon and the Promise of IMPT
Assistant Professor, Radiation Oncology
Chief, Genitourinary Service
Washington University in St. Louis
Dosimetric Effect of Implanted Markers in Pencil Beam Scanning Proton Beam Therapy for Accelerated Partial Breast Irradiation
Hosang Jin, PhD
Department of Radiation Oncology
The University of Oklahoma
First Clinical Experience with HYPERSCAN Pencil Beam Scanning
Brian Collins, MD
Department of Radiation Medicine
MedStar Georgetown University Hospital
If you haven't registered for NAPT 2021, there's still time! Get more information on how to register here and visit Mevion's virtual booth.
Check out the Mev-Ionosphere blog today for more proton therapy updates.